Integra LifeSciences Holdings Corporation IART
Set alert
At close
Pre-market · Nov 3, 7:04 AM ET
- YTD
- +9.58%
- 1 year
- +18.45%
- Open
- 12.98
- Prev close
- 12.75
- Mkt cap
- 1.06B
- Vol
- 1.51M
- Avg vol
- 954.08K
- EPS
- 0.17
- P/E
- 80.06
- Div yield
- 0.00%
More statistics
- Low
- 12.98
- High
- 13.97
- Forward P/E
- 5.70
- Beta
- 1.28
- Short ratio
- 6.30
- Inst. own
- 98.64%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 25, 2027
- 50-d avg
- 14.84
- 200-d avg
- 14.07
- 1y target
- 15.67
News
4 days ago globenewswire.com
Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026…
4 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation ("Integra" or the "Company") (NASDAQ: IART). Such…
6 days ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such…
-
6 days ago benzinga.com
UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14
UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.
-
1 week ago benzinga.com
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.
-
1 week ago benzinga.com
Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.
-
1 week ago benzinga.com
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14
BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.
-
1 week ago benzinga.com
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.
-
1 week ago benzinga.com
Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22
Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.
-
1 week ago benzinga.com
JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target from $17 to $14.
1 week ago benzinga.com
Integra LifeSciences' $2.1B Refinancing Merits A Closer Look
Integra LifeSciences Holdings Corporation (NASDAQ:IART) completed a $2.1 billion refinancing on October 19, 2026. Its revolving credit commitment fell $700 million, from $1.3 billion to $600 million,…
1 week ago benzinga.com
Integra Lifesciences Q3 2026 Earnings Call Transcript
Integra Lifesciences (NASDAQ:IART) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
-
1 week ago benzinga.com
Integra Lifesciences Q3 Adj. EPS $0.59 Beats $0.56 Estimate, Sales $411.182M Miss $414.120M Estimate
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.56 by 5.36 percent. This is a 9.26 percent increase over earnings of…
-
1 week ago benzinga.com
Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.30-$2.40 vs $2.42 Est; Affirms FY2026 Sales Guidance of $1.634B-$1.654B vs $1.661B Est
Integra Lifesciences (NASDAQ:IART) affirms FY2026 Adj EPS guidance from $2.30-$2.40 to $2.30-$2.40 vs $2.42 analyst estimate. Affirms FY2026 sales outlook from $1.634 billion-$1.654 billion to $1.634…
-
1 week ago benzinga.com
Integra Lifesciences Sees Q4 Adj EPS $0.61-$0.71 vs $0.76 Est; Sees Sales $413.000M-$433.000M vs $436.772M Est
Integra Lifesciences (NASDAQ:IART) is looking for Q4 Adj EPS of $0.61-$0.71 vs $0.76 analyst estimate. sees sales of $413.000 million-$433.000 million vs $436.772 million analyst estimate.
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
-
2 weeks ago benzinga.com
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $19 to $15.
4 weeks ago benzinga.com
Flood Damage Prompts Integra LifeSciences To Revise 2026 Outlook
Integra LifeSciences cut its 2026 financial guidance after a July flood disrupted its Cincinnati facility and negatively impacted revenue.
-
4 weeks ago benzinga.com
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15
BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $18 to $15.
1 month ago benzinga.com
Crude Oil Down Over 1%; US Factory Orders Edge Higher In August
U.S. stocks rose Friday, led by Nasdaq (+1.27%), despite weak jobs data. Factory orders edged up; oil and gold fell. Alpha Modus surged 213%.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) shares moved upwards by 66.9% to $6.11 during Friday's regular session. The company's market cap stands at $99.2 million. QTREX Quantum (NASDAQ:QTEX) stock…
-
1 month ago benzinga.com
Integra LifeSciences Anticipates Flooding Related Supply Disruption To Impact Q3 Revenue By ~$7M, Q4 Revenue By $15M - $20M; Expects Q3 Revenue Range Of ~$410M - $412M, Adjusted EPS Range $0.55 - $0.59; Updates FY26 Adjusted EPS Range From $2.40 - $2.50 To $2.30 - $2.40, Revenue Range From $1.654B - $1.695B To $1.634B - $1.654B
Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its…
-
1 month ago benzinga.com
Integra LifeSciences Enrolls 100th Participant In Its AERA Pediatric Registry Observational Registry
Integra LifeSciences (Nasdaq: IART), a leading global medical technology company, announced today the enrollment of the 100th patient in the AERA® Pediatric Registry, a prospective, multicenter…
-
3 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and raises the price target from $15 to $18.
-
3 months ago benzinga.com
Integra Lifesciences Sees Q3 Adj EPS $0.53-$0.61 vs $0.56 Est; Sees Sales $410.000M-$425.000M vs $418.100M Est
Integra Lifesciences (NASDAQ:IART) is looking for Q3 Adj EPS of $0.53-$0.61 vs $0.56 analyst estimate. sees sales of $410.000 million-$425.000 million vs $418.100 million analyst estimate.
-
3 months ago benzinga.com
Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.40-$2.50 vs $2.45 Est; Lowers FY2026 Sales Guidance from $1.662B-$1.702B to $1.654B-$1.695B vs $1.676B Est
Integra Lifesciences (NASDAQ:IART) affirms FY2026 Adj EPS guidance from $2.40-$2.50 to $2.40-$2.50 vs $2.45 analyst estimate. Lowers FY2026 sales outlook from $1.662 billion-$1.702 billion to $1.654…
-
3 months ago benzinga.com
Integra Lifesciences Q2 Adj. EPS $0.56 Beats $0.48 Estimate, Sales $418.761M Beat $418.647M Estimate
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.48 by 16.67 percent. This is a 24.44 percent increase over earnings…
-
3 months ago benzinga.com
UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19
UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral rating and announces Price Target of $19.
-
3 months ago benzinga.com
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price target from $14 to $19.
-
3 months ago benzinga.com
BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19
BMO Capital analyst Vik Chopra initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Market Perform rating and announces Price Target of $19.
-
3 months ago benzinga.com
Citigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $19
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and raises the price target from $16 to $19.
-
6 months ago benzinga.com
Citigroup Maintains Sell on Integra Lifesciences, Raises Price Target to $11
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Sell and raises the price target from $9 to $11.
-
6 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $15
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and raises the price target from $12 to $15.
6 months ago benzinga.com
Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday
Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidance. Other big gainers include EverQuote, Sterling Infrastructure, and DigitalOcean.
6 months ago benzinga.com
Integra Lifesciences Q1 2026 Earnings Call Transcript
Integra Lifesciences Q1 2026 Earnings Call Transcript
-
6 months ago benzinga.com
Integra Lifesciences Sees Q2 Adj EPS $0.44-$0.52 vs $0.53 Est; Sees Sales $410.000M-$425.000M vs $425.403M Est
Integra Lifesciences (NASDAQ:IART) is looking for Q2 Adj EPS of $0.44-$0.52 vs $0.53 analyst estimate. sees sales of $410.000 million-$425.000 million vs $425.403 million analyst estimate.
-
6 months ago benzinga.com
Integra Lifesciences Raises FY2026 Adj EPS Guidance from $2.30-$2.40 to $2.40-$2.50 vs $2.35 Est; Affirms FY2026 Sales Guidance of $1.662B-$1.702B vs $1.674B Est
Integra Lifesciences (NASDAQ:IART) raises FY2026 Adj EPS guidance from $2.30-$2.40 to $2.40-$2.50 vs $2.35 analyst estimate. Affirms FY2026 sales outlook from $1.662 billion-$1.702 billion to $1.662…
-
6 months ago benzinga.com
Integra Lifesciences Q1 Adj. EPS $0.54 Beats $0.41 Estimate, Sales $391.918M Beat $381.870M Estimate
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.41 by 31.71 percent. This is a 31.71 percent increase over earnings…
-
6 months ago benzinga.com
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $12
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $13 to $12.
6 months ago benzinga.com
This Parsons Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings and analysts' views on PSN.
-
8 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $12
Wells Fargo analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $13 to $12.
-
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
-
8 months ago benzinga.com
Integra Lifesciences Sees Q1 Adj EPS $0.37-$0.45 vs $0.48 Est; Sees Sales $375.000M-$390.000M vs $392.147M Est
Integra Lifesciences (NASDAQ:IART) is looking for Q1 Adj EPS of $0.37-$0.45 vs $0.48 analyst estimate. sees sales of $375.000 million-$390.000 million vs $392.147 million analyst estimate.
-
8 months ago benzinga.com
Integra Lifesciences Sees FY2026 Adj EPS $2.30-$2.40 vs $2.35 Est; Sees Sales $1.662B-$1.702B vs $1.675B Est
Integra Lifesciences (NASDAQ:IART) is looking for FY2026 Adj EPS of $2.30-$2.40 vs $2.35 analyst estimate. sees sales of $1.662 billion-$1.702 billion vs $1.675 billion analyst estimate.
-
8 months ago benzinga.com
Integra Lifesciences Q4 Adj. EPS $0.83 Beats $0.80 Estimate, Sales $434.925M Beat $429.621M Estimate
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.80 by 3.75 percent. This is a 14.43 percent decrease over earnings of…
9 months ago benzinga.com
FDA Issues Alert For Integra Wound Care Products Over Infection Fears
FDA warns of high-risk device issue with wound and burn care products by Integra LifeSciences, citing infection risks.
-
9 months ago benzinga.com
FDA Says Integra Lifesciences Identified Packaging Failures Related To MediHoney Wound & Burn Products That Could Lead To A Breach In The Sterile Barrier; Integra Lifesciences Identified Production And Process Control Issues For Certain CVS Wound Gel Products; As Of December 19, 2025, Integra Lifesciences Has Reported 11 Serious Injuries Related To MediHoney Wound And Burn Products, Has Reported 3 Serious Injuries Related To CVS Wound Gel Products; Reported No Deaths Associated
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-wound-and-burn-dressing-issue-integra-lifesciences
-
11 months ago benzinga.com
Integra LifeSciences Gets U.S. FDA's Clearance For Use Of Its CUSA Clarity Ultrasonic Surgical Aspirator System For Cardiac Surgeries
Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its CUSA® Clarity Ultrasonic Surgical…
-
12 months ago benzinga.com
Truist Securities Reiterates Hold on Integra Lifesciences, Lowers Price Target to $13
Truist Securities analyst Ravi Misra reiterates Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.